Department of Ophthalmology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa 920-0293, Japan.
BMC Ophthalmol. 2023 Mar 6;23(1):84. doi: 10.1186/s12886-023-02834-3.
High-dose systemic cytarabine chemotherapy may cause fine corneal opacities and refractile microcysts, which are densely distributed in the center of the cornea. Most previous case reports on microcysts have been those following complaints of subjective symptoms, and the findings at the initial stage of development and time-course changes are still unknown. This report aims to clarify the time-course changes of microcysts using slit-lamp photomicrographs.
A 35-year-old woman who was treated with high-dose systemic cytarabine therapy (3 courses of 2 g/m every 12 h for 5 days) for acute myeloid leukemia and presented with subjective symptoms, such as bilateral conjunctival injection, photophobia, and blurred vision, on the 7 day of treatment in both the first two courses. Anterior segment findings by slit-lamp microscopy revealed microcysts densely distributed in the central region of the corneal epithelium. In both courses, microcysts disappeared within 2-3 weeks upon prophylactic steroid instillation. In the 3 course, daily ophthalmic examinations were conducted from the start of the treatment, and on the 5 day without subjective symptoms, the microcysts in the corneal epithelium appeared evenly and sparsely distributed throughout the cornea except for the corneal limbus. Thereafter, the microcysts accumulated towards the center of the cornea and disappeared gradually. The change from low-dose to full-strength steroid instillation immediately following the occurrence of microcysts in the 3 course resulted in the peak finding being the mildest compared to that in the past two courses.
Our case report revealed that microcysts appeared scattered throughout the cornea before the appearance of subjective symptoms and then accumulated in the center and disappeared. A detailed examination is necessary to detect early changes in microcyst development resulting in prompt and appropriate treatment.
大剂量全身阿糖胞苷化疗可能导致细角膜混浊和折射性微囊,这些微囊密集分布在角膜中央。以前大多数关于微囊的病例报告都是在出现主观症状后报告的,对于其在早期发展阶段和时间过程变化的发现仍不清楚。本报告旨在通过裂隙灯照片阐明微囊的时间过程变化。
一名 35 岁女性,因急性髓系白血病接受大剂量全身阿糖胞苷治疗(3 个疗程,每次 2g/m2,每 12 小时 1 次,连续 5 天),在前两个疗程的第 7 天开始治疗时出现双侧结膜充血、畏光和视力模糊等主观症状。裂隙灯显微镜下眼前节检查显示,角膜上皮中央区域密集分布有微囊。在前两个疗程中,微囊在预防性类固醇滴眼后 2-3 周内消失。在第三个疗程中,从治疗开始每天进行眼部检查,在第 5 天没有主观症状时,角膜上皮中的微囊均匀且稀疏地分布在整个角膜上,除了角膜缘。此后,微囊向角膜中央聚集并逐渐消失。与过去两个疗程相比,在第三个疗程中微囊发生后立即从低剂量改为全剂量类固醇滴眼,导致峰发现象最轻。
我们的病例报告显示,微囊在出现主观症状之前先散在分布在整个角膜上,然后聚集在中央并消失。需要进行详细检查以检测微囊发展的早期变化,从而及时进行适当的治疗。